Goldman Sachs Trims PT on Hologic (HOLX) After Q1, Keeps 'Buy'

February 5, 2013 7:31 AM EST Send to a Friend
Get Alerts HOLX Hot Sheet
Price: $26.93 -0.11%

Rating Summary:
    9 Buy, 17 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade HOLX Now!
Join SI Premium – FREE
Goldman Sachs trimmed its price target on Hologic (NASDAQ: HOLX) from $25 to $24 following in-line Q1 results and below-consensus Q2 guidance after the close but is maintaining a Buy rating.

"We continue to have a bullish long-term outlook on the tomosynthesis cycle, synergy upside from the GPRO acquisition, and the potential for material debt service," the analyst said. "On that basis, we continue to think shares are undervalued and attractive relative to our coverage universe. Having said that, we believe near-term share outperformance will depend on improved revenue growth from a combination of tomo adoption and GPRO product cycles."

Goldman raised FY13 EPS from $1.58 to $1.60, FY14 from $1.90 to $1.94 and FY15 from $2.11 to $2.12.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $23.25 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Goldman Sachs

Add Your Comment